BR112015022208A8 - proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo - Google Patents

proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo

Info

Publication number
BR112015022208A8
BR112015022208A8 BR112015022208A BR112015022208A BR112015022208A8 BR 112015022208 A8 BR112015022208 A8 BR 112015022208A8 BR 112015022208 A BR112015022208 A BR 112015022208A BR 112015022208 A BR112015022208 A BR 112015022208A BR 112015022208 A8 BR112015022208 A8 BR 112015022208A8
Authority
BR
Brazil
Prior art keywords
fusion proteins
pdgf
methods
binding moieties
vegf binding
Prior art date
Application number
BR112015022208A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015022208A2 (pt
Inventor
Scaria Abraham
Rubin Hillard
Ardinger Jeffery
Pechan Peter
Wadsworth Samuel
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112015022208A2 publication Critical patent/BR112015022208A2/pt
Publication of BR112015022208A8 publication Critical patent/BR112015022208A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
BR112015022208A 2013-03-13 2014-03-13 proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo BR112015022208A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361780914P 2013-03-13 2013-03-13
PCT/US2014/026872 WO2014160507A1 (en) 2013-03-13 2014-03-13 Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof

Publications (2)

Publication Number Publication Date
BR112015022208A2 BR112015022208A2 (pt) 2017-10-10
BR112015022208A8 true BR112015022208A8 (pt) 2018-01-23

Family

ID=50680144

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022208A BR112015022208A8 (pt) 2013-03-13 2014-03-13 proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo

Country Status (26)

Country Link
US (4) US9637534B2 (enExample)
EP (1) EP2968461B1 (enExample)
JP (2) JP6561042B2 (enExample)
KR (1) KR102228921B1 (enExample)
CN (1) CN105188733B (enExample)
AR (1) AR095437A1 (enExample)
AU (2) AU2014243712B2 (enExample)
BR (1) BR112015022208A8 (enExample)
CA (1) CA2904623A1 (enExample)
DK (1) DK2968461T3 (enExample)
ES (1) ES2933558T3 (enExample)
FI (1) FI2968461T3 (enExample)
HR (1) HRP20221447T1 (enExample)
HU (1) HUE060464T2 (enExample)
IL (2) IL240950B (enExample)
LT (1) LT2968461T (enExample)
MX (1) MX363533B (enExample)
PL (1) PL2968461T3 (enExample)
PT (1) PT2968461T (enExample)
RS (1) RS63820B1 (enExample)
RU (1) RU2692652C2 (enExample)
SG (3) SG10201912956YA (enExample)
SI (1) SI2968461T1 (enExample)
TW (1) TWI631133B (enExample)
UY (1) UY35407A (enExample)
WO (1) WO2014160507A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
SG10201912956YA (en) 2013-03-13 2020-02-27 Genzyme Corp Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof
JP2016522249A (ja) * 2013-06-20 2016-07-28 ノバルティス アーゲー 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用
PL3041513T3 (pl) 2013-09-08 2021-01-25 Kodiak Sciences Inc. Obojnaczojonowe polimerowe koniugaty czynnika viii
KR101819135B1 (ko) 2014-03-18 2018-01-18 한국과학기술원 당화 vegf 디코이 수용체 융합 단백질
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3161000A4 (en) * 2014-06-28 2018-05-02 Kodiak Sciences Inc. Dual pdgf/vegf antagonists
WO2016061562A2 (en) 2014-10-17 2016-04-21 Kodiak Sciences Inc. Butyrylcholinesterase zwitterionic polymer conjugates
ES2873379T3 (es) 2015-03-11 2021-11-03 Allgenesis Biotherapeutics Inc Proteína de fusión que comprende un dominio de unión a ligando de VEGF y PDGF
CA2987884C (en) * 2015-06-28 2023-01-03 Allgenesis Biotherapeutics Inc. Fusion peptides comprising disintegrin binding to integrin .alpha.v.beta.x or .alpha.5.beta.1 and their use in treating an angiogenic disease
WO2017084616A1 (en) * 2015-11-19 2017-05-26 Zhuhai Tairuishang Biopharm Ltd. Methods and compositions for binding vegf
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
MX2018011865A (es) 2016-03-30 2019-03-28 Ab biosciences inc Composiciones de inmunoglobulina intravenosa recombinante (rivig) y metodos para su produccion y uso.
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
JP6849390B2 (ja) * 2016-10-28 2021-03-24 花王株式会社 関節のこわばり改善剤
EP3697896A1 (en) * 2017-10-16 2020-08-26 Vigeneron GmbH Aav vectors
KR102205830B1 (ko) * 2017-10-26 2021-01-21 주식회사 큐로진생명과학 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
WO2019083171A2 (ko) * 2017-10-26 2019-05-02 주식회사 큐로진생명과학 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물
CN111406071B (zh) * 2017-11-16 2024-01-16 成都硕德药业有限公司 Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途
WO2019096226A1 (en) * 2017-11-16 2019-05-23 Chengdu Easton Biopharmaceuticals Co., Ltd. Pasylated vegfr/pdgfr fusion proteins and their use in therapy
SG11202007130RA (en) * 2018-01-26 2020-08-28 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
US20230024569A1 (en) * 2019-12-04 2023-01-26 Cdmogen Co., Ltd. Composition for treating diabetic retinopathy, comprising raav containing soluble vegfr-1 variant cdna
CN111826400A (zh) * 2020-07-21 2020-10-27 中科宝承生物医学科技有限公司 一种双特异性抗体nk细胞制备方法及其细胞和应用
CN112961250B (zh) * 2021-03-01 2023-06-06 长春金赛药业有限责任公司 抗体融合蛋白及其应用
CN113105558A (zh) * 2021-04-01 2021-07-13 芜湖英特菲尔生物制品产业研究院有限公司 一种酿酒酵母表达人rPDGF-HSA融合蛋白及其标准品的制备方法
US20240285800A1 (en) * 2021-06-18 2024-08-29 Ikarovec Limited Retinal Disorders
WO2023199951A1 (ja) * 2022-04-13 2023-10-19 株式会社セルージョン 抗ｖｅｇｆ機能を有する多能性幹細胞及びその分化細胞
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
JP2025530910A (ja) 2022-08-02 2025-09-18 パノロスバイオサイエンスインク 修飾された融合タンパク質及びその用途
WO2025033876A1 (ko) * 2023-08-04 2025-02-13 주식회사 파노로스바이오사이언스 변형된 융합 단백질과 scFv의 결합체 및 이의 용도
WO2025042305A1 (ru) * 2023-08-18 2025-02-27 Общество с ограниченной ответственностью "Пальмира Биофарма" Нуклеотидная последовательность, кодирующпя слитый белок pdgfra-hfc

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4952515A (en) 1987-05-22 1990-08-28 Polymer Technology International Corp. Method of detection using a test strip having a non particulate dialyzed polymer layer
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
AU1411092A (en) 1991-01-31 1992-09-07 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2308989T3 (es) 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AU6972301A (en) 2000-06-01 2001-12-11 Univ North Carolina Duplexed parvovirus vectors
US20030181531A1 (en) 2003-02-11 2003-09-25 David Sherris Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
AU2003218168A1 (en) 2002-03-15 2003-09-29 University Of Southern California Ophthalmic solutions for delivery of expression vectors
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
DE602005021811D1 (de) * 2004-09-13 2010-07-22 Genzyme Corp Multimere konstrukte
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
DE102005020510A1 (de) 2005-04-29 2006-11-09 Basf Ag Verbundelement, insbesondere Fensterscheibe
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
BRPI0908496A2 (pt) 2008-02-20 2019-01-15 Genzyme Corp inibição de angiogênese
SI2274008T1 (sl) * 2008-03-27 2014-08-29 Zymogenetics, Inc. Sestavki in metode za zaviranje PDGFRBETA in VEGF-A
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
CN102311502B (zh) * 2010-07-10 2013-12-25 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其医疗应用
EP2646007B1 (en) * 2010-12-02 2016-12-21 Neurotech USA, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
SI2691417T2 (sl) 2011-03-29 2025-05-30 Roche Glycart Ag FC variante protitelesa
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
SG10201912956YA (en) 2013-03-13 2020-02-27 Genzyme Corp Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof

Also Published As

Publication number Publication date
EP2968461A1 (en) 2016-01-20
AU2014243712A1 (en) 2015-10-15
TWI631133B (zh) 2018-08-01
MX2015011951A (es) 2016-04-07
WO2014160507A1 (en) 2014-10-02
PT2968461T (pt) 2022-12-26
HRP20221447T1 (hr) 2023-01-20
AR095437A1 (es) 2015-10-14
UY35407A (es) 2014-10-31
US20140315804A1 (en) 2014-10-23
KR102228921B1 (ko) 2021-03-16
FI2968461T3 (fi) 2023-01-13
SI2968461T1 (sl) 2023-01-31
EP2968461B1 (en) 2022-09-21
AU2018278902A1 (en) 2019-01-03
DK2968461T3 (da) 2022-12-19
ES2933558T3 (es) 2023-02-10
US20220064262A1 (en) 2022-03-03
SG10201707501TA (en) 2017-10-30
MX363533B (es) 2019-03-27
TW201506038A (zh) 2015-02-16
BR112015022208A2 (pt) 2017-10-10
RU2692652C2 (ru) 2019-06-25
SG10201912956YA (en) 2020-02-27
JP2019123711A (ja) 2019-07-25
LT2968461T (lt) 2022-12-27
RS63820B1 (sr) 2023-01-31
CN105188733A (zh) 2015-12-23
IL240950B (en) 2019-06-30
HK1220618A1 (en) 2017-05-12
RU2015142999A (ru) 2017-04-17
PL2968461T3 (pl) 2023-01-30
IL240950A0 (en) 2015-11-30
IL266715A (en) 2019-07-31
KR20150126923A (ko) 2015-11-13
CN105188733B (zh) 2020-05-08
US11084864B2 (en) 2021-08-10
US10183983B2 (en) 2019-01-22
AU2014243712B2 (en) 2018-09-13
CA2904623A1 (en) 2014-10-02
SG11201506802SA (en) 2015-09-29
US9637534B2 (en) 2017-05-02
US20190345223A1 (en) 2019-11-14
US20170342127A1 (en) 2017-11-30
JP2016513669A (ja) 2016-05-16
JP6561042B2 (ja) 2019-08-14
HUE060464T2 (hu) 2023-03-28

Similar Documents

Publication Publication Date Title
BR112015022208A8 (pt) proteínas de fusão que compreendem pdgf e partes de ligação de vegf, e métodos de utilização do mesmo
EA201391175A1 (ru) Гетеродимерные иммуноглобулины
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2016007063A (es) Peptidos terapeuticos.
EP2929045A4 (en) PROTEIN EXPRESSION REINFORCING POLYPEPTIDES
IL243209B (en) Cyclic peptides as protein targeting agents
MX2019007921A (es) Nuevos agentes de union a ha.
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
EP2905290A4 (en) HETERODIMER PROTEIN COMPOSITION
DK2940135T3 (da) Heterodimeriseret polypeptid
EP2822575A4 (en) MANIPULATED ANTIBODY-INTERFERON-MUTANT FUSION MOLECULES
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
CL2016000219A1 (es) Proteinas de fusión terapéutica.
CY1120824T1 (el) Μεθοδοι αυξησης περιεχομενου μαννοζης ανασυνδυασμενων πρωτεϊνων
MX2016002166A (es) Anticuerpos.
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
IL232645B (en) Recombinant proteins and their therapeutic uses
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
EP2812018A4 (en) NOVEL SP-B AND SP-C PEPTIDES, TENSIDES FOR A SYNTHETIC LUNGE AND USE THEREOF
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
HUE050362T2 (hu) Javított rekombináns fehérje expresszió hibrid CHEF1 promótert alkalmazva
CR20160444A (es) Proteínas de fusión uti

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2713 DE 03-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.